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Gastric cancer (GC) remains a malignant disease with high mortality. Patients are frequently diagnosed in advanced
stages where survival prognosis is poor. Thus, there is high medical need to find novel drug targets and treatment
strategies. Recently, the comprehensive molecular characterization of GC subtypes revealed mutations in the small
GTPase RHOA as a hallmark of diffuse-type GC. RHOA activates RHO-associated protein kinases (ROCK1/2) which
regulate cell contractility, migration and growth and thus may play a role in cancer. However, therapeutic benefit of
RHO-pathway inhibition in GC has not been shown so far. The ROCK1/2 inhibitor 1-(5-isoquinoline sulfonyl)-
homopiperazine (HA-1077, fasudil) is approved for cerebrovascular bleeding in patients. We therefore investigated
whether fasudil (i.p., 10mg/kg per day, 4 times per week, 4 weeks) inhibits tumor growth in a preclinical model of GC.
Fasudil evoked cell death in human GC cells and reduced the tumor size in the stomach of CEA424-SV40 TAg
transgenic mice. Small animal PET/CT confirmed preclinical efficacy. Mass spectrometry imaging identified a
translatable biomarker for mouse GC and suggested rapid but incomplete in situ distribution of the drug to gastric tumor
tissue. RHOA expression was increased in the neoplastic murine stomach compared with normal non-malignant gastric
tissue, and fasudil reduced (auto) phosphorylation of ROCK2 at THR249 in vivo and in humanGCcells in vitro. In sum, our
data suggest that RHO-pathway inhibition may constitute a novel strategy for treatment of GC and that enhanced
distribution of future ROCK inhibitors into tumor tissue may further improve efficacy.
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Gastric cancer (GC) is the third leading cause of cancer-related death
world-wide [1,2]. Patients frequently present with advanced stage GC
where curative treatment is not possible and the 5-year overall survival rate
is less than 30%. Thus, novel treatment options need to be developed.
Comprehensive genomic approaches have recently classified molecular
subtypes of GC into at least four different genetic profiles [3–5]. In this
context, three seminal papers corroborated the small GTPase RHOA as a
major oncogenic driver mutation for the diffuse-type GC in humans
(Kakiuchi et al., 2014 [5]; Wang et al., 2014 [4]; TCGA, 2014 [3]). The
RHOA-signaling pathway is activated by integrins, growth factor,
cytokine and G-protein-coupled receptors in response to signals from
extracellular matrix and adhesion molecules, hormones and nutrients [6].
ActiveGTP-boundRHOAbinds to a wide series of downstream effectors
(N20), for example the RHO-associated protein kinases (ROCK1/2), and
leads to an allosteric activation of the serine/threonine kinase domain and
to autophosphorylation [7–10]. The ROCK1 and 2 enzymes are partially
redundant, although tissue specific distribution has been reported. They
phosphorylate an array of substrate proteins including cytoskeleton
components such as myosin light chain (MLC) that promote cell
contractility, adhesion and migration in normal and malignant cells.
Thereby, ROCKs regulate cellular functions such as growth, invasion and
cell viability and are involved in hypertension, Alzheimer's disease and
cancer [11–13]. Hence, ROCK1/2 are attractive drug targets for disease
prevention or therapy. Potent and selective ROCK1/2 inhibitors are
under current (pre)clinical development, with fasudil [1-(5-isoquinoline
sulfonyl)-homopiperazine] (HA-1077) approved for the clinical treat-
ment of cerebral vasospasms during subarachnoid hemorrhage in China
and Japan [14]. The compound has been shown to exert anti-tumor
efficacy in rodent xenografts including breast, myeloma, lung, melanoma,
glioblastoma and head-and-neck cancer [15–18].
RHO and ROCK isoforms are expressed in human GC cells
[19,20], and RHOA expression and/or mutations have been
associated with poor clinical prognosis in patients with diffuse GC
[21–23]. Inhibition of RHOA/ROCK signaling promotes apoptosis
and reduces proliferation of human GC cells [24–26]. We therefore
hypothesized that pharmacological inhibition of ROCK1/2 by fasudil
may exert therapeutic benefit in vivo, in mice with spontaneous
genetically driven gastric carcinoma as a preclinical model of human
GC. The transgenic C57BL/6 J mouse strain CEA424-SV40 TAg
expresses the viral oncogene “large T-antigen” (TAg) from the Simian
Virus 40 (SV40) under the control of the promoter of the human
carcinoembryonic antigen (CEA) specifically in the lower part of the
stomach (pylorus) and develops highly proliferative intraepithelial
gastric carcinomas within 2 months of age and with 100% penetrance
[27]. We show here both in situ drug distribution and metabolism
together with preclinical efficacy of fasudil on tumor growth in vivo in
murine GC and in vitro in human GC cell lines. In sum, our data
propose that inhibition of the “oncogenic driver” RHO signaling
pathway by marketed ROCK1/2 inhibitors may constitute a future
novel therapy of human GC that could be further improved by next
generation drugs with enhanced tumor penetration.
Materials and Methods
Animals
Transgenic CEA424-SV40 TAg C57BL/6 J mice with gastric
carcinoma were described elsewhere [27,28]. Animal studies were
conducted in agreement with ethical guidelines of the University of35–9185.82/G-176/12).
Reagents
Acetonitrile (ACN), trifluoroacetic acid (TFA) and general
chemicals were from Merck (Darmstadt, Germany) or
Sigma-Aldrich (Steinheim, Germany). Fasudil was from Selleckchem
(Houston, TX). Antibodies were phosphorylated (P) P-ROCK2
(T249, #ab83514, Abcam, Cambridge, UK), Ki67 (#550609),
unphosphorylated/general (G) G-ROCK2 (#610624) (both from BD
Biosciences, Heidelberg, Germany), RHOA (STA-403-A-CB, Biocat,
Heidelberg, Germany), P-MLC2 (#3671), P-ERK1/2(p44/p42)
(#4370), G-ERK1/2(p44/p42) (#9102), P-P38 (#4511), G-P38
(#9218) (all from Cell Signaling), HSP90 (sc-7947, Santa Cruz Biot.,
CA). MALDI peptide calibration standard II (#222570), 2,5-dihy-
droxybenzoic acid (DHB, #209813) and indium tin oxide (ITO) slides
were from Bruker Daltonik (Bremen, Germany), Isopentane (GPR
RECTAPUR) from VWR (Darmstadt, Germany), FSC22 Frozen
Section Compound from Leica Biosystems (Wetzlar, Germany) and
Tissue-Tek Cryomolds from Sakura Finetek (Heppenheim, Germany).
[18F]-FDG was purchased from ZAG Zyklotron AG (Karlsruhe,
Germany).
Cell Culture and Assays
Human embryonic kidney cells transformed with SV40 large
T-Antigen (HEK293T) and GC cell lines (AGS, MKN45) (all from
the American Type Culture Collection, Rockville, MD) were
maintained as described previously [29]. Cell viability was measured
by 1-(4,5-dimethylthiazol-2-yl) 3,5-diphenyl-formazan (MTT) assay
(Roche Diagnostics GmbH, Mannheim, Germany) as recommended
by the manufacturer.
Protein Extraction, GTPase Pull-Down, Immunoprecipitation
(IP) and Western Blot (WB)
All methodologies were performed as described before [30].
RHOA GTPase pull-down assay was performed as recommended by
the manufacturer (STA-403-A-CB, Biocat, Heidelberg, Germany).
Immunohistochemistry (IHC) and Immunofluorescence
(IF) Microscopy
Hematoxylin-eosin (H&E) and antibody stainings were performed
as described [29,30]. For IHC, 3,3′-diaminobenzidine was used as a
substrate (brown color). IF stainings were analyzed using a
fluorescence microscope (Axiovert 200 M, Carl Zeiss MicroImaging
GmbH, Germany) and software (Axiovision, release 4.4). Manual
counting of signals (n N 50 per field, n = 5 fields per image) was done
with Image J (imagej.nih.gov/ij).
Reverse Transcription PCR (RT-PCR) and Quantitative
PCR (qPCR)
Primers are listed in Table S1. All methods were conducted as
published [30,31].
MALDI-MS Imaging
Male C57BL/6 J and CEA424-SV40TAg transgenic mice (C57BL6
background) (3 months of age, average body weight 20 g) received food
and water ad libitum until 3 h before drug administration. Fasudil
monohydrochloride [1-(5-isoquinolinesulfonyl)-homopiperazine]
(HA-1077) was dissolved in sterile PBS and administered i.p. as a
single dose of 30 mg/kg. Animals were treated for 10, 30, or 60 min
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tissues were dissected, washed with PBS and immediately frozen in
cryomolds above a pre-cooled isopentane bath in liquid N2. Organs
were stored at −80°C until analysis. Frozen organs were mounted onto a
pre-cooled metal chuck using a minimal amount of tissue freezing
medium and cut into 10 μm sections using a cryostat CM1950 (Leica
Biosystems, Nussloch, Germany) at a temperature of −15°C. Tissue
sections were thaw-mounted onto ITO slides and subsequently
desiccated at room temperature (RT) for two hours until matrix
application. DHB matrix was prepared at a concentration of 60 mg/ml
in ACN/H2O/TFA (50:49.5:0.5, v/v/v). Matrix application to the
tissue sections was performed by spray coating using a SunCollect
sprayer (SunChrom, Friedrichsdorf, Germany). Thematrix was applied
in five layers in ascending flow rates (10, 15, 20, 20, 20 μL/min). Data
acquisition was performed on an UltrafleXtreme MALDI-TOF/TOF
mass spectrometer (Bruker Daltonik, Bremen, Germany) equipped
with a 2000 Hz Smartbeam-II laser. Spectra and images were acquired
in the positive reflectron ion mode within the mass range of m/z
100–1500 Da using the FlexControl 3.4 software (Bruker Daltonik).
Prior to analysis, the acquisitionmethod was calibrated externally on the
ITO slide using the DHB matrix peak (m/z 155.0344), Fasudil (m/z
292.1114), Donepezil (m/z 380.2220) and the peptide calibration
Standard II (Bruker Daltonik). Fasudil imaging was performed using
the FlexImaging 3.0 software (Bruker Daltonik) by accumulating 500
laser shots per measurement spot at a raster width of 100, 50, or 25 μm
as indicated. For MALDI-MS/MS imaging of fasudil, a window range
of ±3 Da was utilized for parent mass selection and fragment spectra
were acquired from each position by accumulating 500 shots using a
calibrated LIFT method. The piperazine fragment was selected for the
MS/MS imaging process for both fasudil and hydroxyfasudil due to its
superior sensitivity. Fourier transform ion cyclotron resonance (FTICR)
MS analysis was performed at Bruker Daltonik (in Bremen, Germany)
on a 12 T instrument (solariX, Bruker Daltonik) equipped with a dual
ESI/MALDI ion source using FT MS Control 2.1 (Bruker Daltonik).
MS/MS single spectra on tissue for molecule identification purposes
were acquired using sustained off resonance irradiation (SORI, notch
window of 0.1 Da) in the ICR cell with an upfront quadrupole isolation
window of 10 Da by recording 10 scans using the ions generated by
accumulating 200 laser shots each on the tissue. Imaging data were total
ion count (TIC) or DHB matrix (m/z window 154.8–155.3)
normalized and visualized by FlexImaging 3.0.
PET/CT Imaging
Female CEA424-SV40 TAg transgenic mice (C57BL6/J background) (2
months of age, average body weight 20 g) received repetitive injections of
fasudil (i.p., 10 mg/kg*day, 4 times per week) or PBS (control) for 4 weeks,
respectively (n = 12 animals per group). Fasudil dissolved in sterile PBS was
administered i.p. as a single dose of 10mg/kg per day.The animals had access
to food andwaterad libitumuntil 3 hbefore radioactive tracer administration.
Micewere anesthetized by inhalation of a mixture of O2/isofluorane and
injected with a single dose of [18F]-FDG (~5 MBq in 150 μl sterile
0.9% (w/v) NaCl solution) in the tail vein (i.v.). For optimal tracer
distribution, mice were kept under anesthesia for 60 min below a red
warming lamp. One to 3 mice were measured using the multi-animal
transport system (MATS, Bruker Biospin, Ettlingen, Karlsruhe,
Germany). A dynamic scan starting 60 p.i. was performed over 30
min, and a subsequent CT image was acquired using a tri-modal Bruker
Albira II small-animal PET/SPECT/CT (Bruker Biospin GmbH)
[35,36]. Thereafter, mice were sacrificed and organs snap-frozen orfixed in formalin for paraffin embedding. 3D-reconstruction software
and calculation of standard uptake volume (SUV) and tumor volume
(in cm3) within the region of interest (ROI) was conducted
reconstructing images with 35 iterations and using PMOD v.3.608
for data analysis (PMOD, Zurich, Switzerland) as published [35,36].
To reduce reader bias, the images were analyzed rater-blinded.
Statistics
Results are means ± S.E. from at least 5 animals per genotype or 3
independent experiments from different cell passages. The software
Graphpad Prism (version 4.0) was used to analyze the data. Pb.05
was considered significant. All tests were unpaired and two-tailed.
Results
Expression of RHOA and ROCK1/2 in Human and Murine
GC Cells and Tissues
To test for expression and activity of RHO-pathway components, the
HEK293T cell line [37] was used as an appropriate in vitro model for
ROCK1/2 inhibition. This cell line had been transformed by the SV40
large T-antigen (TAg), the same viral oncogene which was overexpressed in
the transgenicmousemodel used in this study [27], andTAg shown to alter
cell migration and invasion by interfering with the regulation of
cytoskeleton components by small GTPases (Rac1, Cdc42) [38,39]. To
measure RHOA activity, pull-down assays were conducted using
recombinant GST-rhotekin as bait for GTP-bound active RHOA. WBs
of the precipitates detected only low amounts of active RHOA in contrast
to total RHOAprotein in the input controls. This observationwas the same
forHEK293T andGCcell lines (AGS,MKN45) (Figure 1A).WBanalysis
of total cell lysates (TCLs) confirmed the steady-state expression of
RHOA and ROCK2 proteins in cycling cells (Figure 1B). In AGS cells,
which had been treated with fasudil (FASU) for 30 h, the amount of
phosphorylated ROCK2 at T249 (P-ROCK2) was reduced by ~26%
(n = 3, P= .0006 FASU vs. PBS, t-test) compared to total ROCK2.
Phosphorylation of the cognate ROCK1/2 substrate myosin light
chain-2 (MLC2) was also decreased confirming the in vitro efficacy of
the compound. RT-qPCRs on total RNA, extracted from cycling cells,
corroborated expression of RHOA and ROCK1/2 mRNAs (S1). These
results indicated that the fasudil targets ROCK1/2 are expressed in
human TAg- transformed and GC cell lines, however, the RHOA
enzyme was not in an active state as suggested from the RHOA
mutations identified in human GC tissue [4–6].
To test whether ROCK-inhibition reduces cell viability in vitro,
AGS and MKN45 cells were grown to confluency and treated with
vehicle (PBS) or increasing concentrations of fasudil for 48 h. Cell
viability was measured by colorimetric MTT assay (Figure 1C). Fasudil
reduced cell viability to 35 ± 2% (at 0.2 mM in AGS) and 52 ± 6%
(at 0.5 mM in MKN45) compared with vehicle-treated cells (n = 3 per
cell line, Pb .01 FASU vs. PBS, Mann-Whitney U test).
We next asked whether the targets of fasudil are also present in
mouse tissues in vivo. WB analysis of total tissue lysates evinced a
significantly increased expression of RHOA (2-fold; P= .0084) and
P-ROCK2 (11-fold; P= .0306) protein (n = 5 mice per genotype, NT
vs. TU; t-test) in gastric tumor tissue (TU) compared with normal
gastric tissue (NT) of CEA424-SV40 TAg mice (Figure 2A)
RT-qPCRs on total RNA extracted from mouse tissues confirmed
expression of Rhoa and Rock1/2 mRNAs (S1). To determine RHOA
activity in vivo, pull-down assays were conducted in total tissue lysates
from NT and TU stomachs. WBs detected no GTP-bound active
RHOA. However, there was again a 4-fold increase in total RHOA
Figure 1. Expression of RHOA and ROCK2 in human transformed and GC cell lines. A, Human GC cell lines (AGS, MKN45) and HEK293 cells
transformed with large T-antigen (TAg) express total RHOA but not active RHOA protein. Cells were grown to confluency followed by
GST-pulldown fromTCLsusing recombinant rhotekin-GDSprotein asbait for precipitationof activeGTP-boundRHOAprotein. Precipitated active
RHOAwas then detected together with total RHOA protein (“input”=TCL before pulldown) byWestern blots (WB) using a RHOA p21 Ab. O.D.
values from bands in gels were normalized to HSP90 (loading control) and calculated as -fold ± S.E. compared with control (n = 3 per cell line;
inputP= .039 andpulldownP= .021MKN45 vs.AGS, KruskalWallis test). Quantitative analyses and representative gels are shown.B, Cellswere
treatedwith vehicle (PBS,−) or fasudil (FASU, +) for 30 hours beforeWB of total cell lysates. O.D. values from bands in gels were normalized to
HSP90 (loading control) and calculated as -fold ± S.E. (n = 3 per cell line; P= .0006 FASU vs. PBS, t-test) compared with vehicle control.
Quantitative analyses and representative gels are shown. C, ROCK1/2 inhibition promotes cell death. Cells were treated with vehicle (PBS) or
increasing concentrations of fasudil for 48 hours, and cell viability was measured by colorimetric MTT assay after 2 days. O.D. values were
calculated as % ± S.E. (n = 3 per cell line, P= .0078 and P= .0001 FASU vs. PBS, Mann-Whitney U test) compared with vehicle control.
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indicated that gastric tumors of CEA424-SV40 TAg mice express
elevated levels of RHOA and phosphorylated ROCK1/2, proposing
this pathway as a target for the ROCK-inhibitor fasudil.
MALDI-MSI Detects Fasudil Distribution to Normal Stomach
and Gastric Tumor Tissue in CEA424-SV40 TAg Mice
In order to visualize the in situ distribution of fasudil and its
pharmacologically active metabolite hydroxyfasudil, wild-type (WT)Figure 2. Expression of RHOA and ROCK2 in murine GC tissue. A, E
tissue. Total tissue lysates from WT normal (NT) and transgenic stom
and phosphorylation-specific Abs. Representative gels are shown. O.D
as -fold ± S.E. (n = 5 mice, *Pb .05 NT vs. TU, t-test).B, Murine gastri
RHOA protein. Pull-down assays for GTP-bound RHOA from whol
precipitated and served as a control for equal loading (input). O.D. valu
NT vs. TU, t-test).and transgenic CEA424-SV40 TAg mice received an intraperitoneal
(i.p.) injection of a single 30 mg/kg dose of fasudil or PBS as vehicle
control before being sacrificed. Frozen tissues were collected for
MALDI-MSI and histological processing. Because the half-life of
fasudil is very short (9.3 min at 10 mg/kg i.p. in mice) [40], the time
points 0, 10, 30 and 60 min were selected for analysis (n = 2
CEA424-SV40 TAg and n = 1WT animal per time point) (Figure 3A).
The parent drug was detected in liver tissue already 10 min after
administration of the compound (Figure 3B). Metabolism tolevated expression of RHOA and P-ROCK2 proteins in murine GC
achs with gastric tumors (TU) were subjected to WB using general
. values of bands in gels were normalized to HSP90 and calculated
c tumor tissue expressed high amount of total RHOA but not active
e tissue lysates were performed as in Figure 1. HSP90 was not
es from band in gels were calculated as in A (n = 3 mice, P= .0875
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xyfasudil is approximately four times longer than that of fasudil (36.4min
at 10mg/kg i.p. inmice) [40]. Themass spectra demonstrated that fasudil
and hydroxyfasudil rapidly accumulated in the WT and transgenic liver
tissues within 10–30 min after drug administration (Figure 3D).
More importantly, fasudil was visualized by mass spectrometry in
all anatomical stomach regions. Fasudil distribution into stomach and
its metabolism to the active metabolite hydroxyfasudil were effective
(Figure 4A). HE-staining of corresponding cryosections was
performed to assess the histopathology and to delineate the tumor
foci and the overall anatomy of the organ. An unbiased comparison of
MS signals in the tumor region vs. stroma tissue was performed by
fold-change calculations and statistical tests. Several masses were
specifically elevated in the tumor area and can be considered putative
tumor markers. One of them, m/z 798.5, was used to highlight the
tumor area in the MS images (Figure 4A). Distribution of the drug to
tumorous and non-tumorous tissue was not homogeneous. FasudilFigure 3. MALDI-MS drug imaging in liver tissue from WT and CEA
metabolite hydroxyfasudil in mouse liver by MALDI MSI following
UltrafleXtreme MALDI-TOF/TOF instrument. Fasudil signals were first
confirmed in MS/MS mode measuring with a 50 μm offset in x an
confirmed by MS/MS measurements on an adjacent measurement r
intensities in arbitrary units. Note that fasudil distributes and metabol
fasudil with characteristic MS/MS fragment. C, Structural formula of
peak normalized drug and metabolite signal intensities of WT (n = 4) a
fasudil and hydroxyfasudil were added and displayed for the control a
WT and two tumor animals each. Statistical analysis was performed u
mice per group, *Pb .05).signal intensities were higher in columnar epithelia of the gastric
corpus and in parts in the squamous epithelia of the forestomach.
There was no obvious enrichment of fasudil or hydroxyfasudil in the
tumor areas compared with the non-malignant regions of the
stomach. The distribution of hydroxyfasudil was identical to its
precursor. Nevertheless, a significant amount of fasudil (Figure 4B)
and hydroxyfasudil (Figure 4C) was able to distribute to the gastrointestinal
tumor. These findings suggested that the drug reached the target organ of
interest (S2) without being selective for tumor cells (S3). The putative
tumor marker with the precise mass 798.541 was identified as potassium
adducted phosphatidylcholine PC(34:1) by MALDI FTICR (Fourier
transform ion cyclotron resonance) tandemmass spectrometry (S4). In situ
distribution of this PC, as assessed by MALDI-FTICR imaging (S5)
corroborated the notion that tumor regions can be precisely identified and
located. Importantly, PC(34:1)+K+ has been described by Uehara et al.
[41] as a marker of gastric carcinoma in patients. Our results suggest that it
may be a translational marker from mice to humans.424-SV40 TAg mice. A, In situ detection of fasudil and its active
i.p. dosing. Drug distribution in liver was measured using an
measured in MS mode at a raster size of 100 μm and subsequently
d y direction on the same tissue. The hydroxyfasudil signal was
egion. Displayed are TIC normalized ion images of absolute signal
izes rapidly to hydroxyfasudil in liver tissue.B, Structural formula of
hydroxyfasudil with characteristic MS/MS fragment.D, DHB matrix
nd CEA424-SV40 TAg (n = 8) mice. Normalized signal intensities of
nimals (ctrl) and the 10 min, 30 min and 60 min time points for one
sing the 1-way ANOVA Dunnett's Multiple Comparison Test (n = 3
Figure 4. MALDI-MS drug imaging in stomach tissue from CEA424-SV40 TAg mice. A, MALDI-MSI showing an overlay of signals for
fasudil, hydroxyfasudil and the lipid tumor marker candidate PC(34:1)+K+ in regions of the mouse normal stomach and GC tissue.
Cryosections from fasudil-treated CEA424-SV40 TAg mice were analyzed 30 min after i.p. dosing. Drug distribution was measured in
positive ion reflector mode at a spatial resolution of 50 μm (above) and 25 μm (below) with 500 laser shots per position. The colored scale
bars indicate the signal intensity as absolute values in arbitrary units. Merge: Displayed are the TIC-normalized ion images of PC (green),
fasudil (red) and hydroxyfasudil (blue) of the dosed stomach tissue. The representative MALDI-MSI image is shown together with the
corresponding H&E staining.B, Fasudil distributes to gastric tumor tissue. Cryosections from eight CEA424-SV40 TAg mice were
analyzed. Three regions of interest (ROIs) of a size of 1 mm2 (equivalent to 100 spectra) were selected arbitrarily in the tumor region of the
control animals (n = 2) and in the tumor region of the fasudil treated animals (n = 6). Spectra were normalized to the DHB matrix peak
and signal intensities of the PBS-treated control tumors (−) were compared with fasudil-treated tumors (+). Average signals of fasudil and
C, hydroxyfasudil in tumorswere elevated comparedwith control (*P= .0006 TU FASU vs. TU PBS for fasudil and *P= .0004 TU FASU vs. TU
PBS for hydroxyfasudil; Mann-Whitney U tests).
506 ROCK-inhibition and Gastric Cancer Hinsenkamp et al. Neoplasia Vol. 18, No. 8, 2016PET/CT Imaging Visualizes Preclinical Efficacy of Fasudil
in GC of CEA424-SV40 TAg Mice
To determine whether ROCK1/2-inhibition inhibits tumor
growth in vivo, transgenic (CEA424-SV40 TAg) mice received an
intraperitoneal (i.p.) injection of 10 mg/kg dose (4 times per week) of
fasudil or PBS for a total time frame of 4 weeks. Mice were deprivedof food for 3 hours and then anesthetized and i.v. injected with
[18F]-FDG for PET/CT imaging. The overlay of PET/CT images
from treated and control mice (Figure 5A) demonstrated that the
gastric tumor was localized below the heart and between the kidneys
in the paraxial mode of 3D-visualization. High-resolution images of
axial and coronal views are presented in the supplement (S6, S7 and
Neoplasia Vol. 18, No. 8, 2016 ROCK-inhibition and gastric cancer Hinsenkamp et al. 507movies). WT mice stomachs did not emit any signal in the equivalent
anatomical area (not shown). Quantitative calculation of the 3D
tumor volumes revealed reduction of [18F]-FDG uptake and signal
intensity from 0.071 ± 0.013 to 0.030 ± 0.009 cm3 (n = 12 mice per
group, P= .0089 FASU vs. PBS over all SUV ranges, Mann-Whitney
U test) by fasudil compared with PBS controls (Figure 5B).
After acquisition of live imaging, mice were sacrificed, and tissues
were collected and snap-frozen or formalin fixed and processed for
paraffin embedding. Measurement of the tumor regions on
HE-stained tissue sections of the stomachs revealed a decrease of
the 2D tumor areas from 1.696 ± 0.096 to 1.254 ± 0.100 mm2 (n =
23 mice per group, P= .0021 FASU vs. PBS , Mann-Whitney U test)
by fasudil compared with the PBS controls (Figure 5C). Detection of
Ki-67 by immunohistochemistry (IHC) showed that the number of
proliferating cells in the gastric tumor was reduced in fasudil-treated
mice from 150 ± 25 to 68 ± 19 compared with PBS controls (1 field =
0.3 mm2, n = 5 fields per mouse, n = 4 mice per group, P= .0407
FASU vs. PBS, t-test) (Figure 5D). There were no signs of massive
intratumoral necrosis or drug-related apoptosis upon fasudil
administration. Taken together, this data demonstrated for the first
time that RHO-pathway inhibition reduces growth of GC in vivo.
Fasudil Lowers RHO-Pathway Signaling in Murine GC
To confirm the expression of the fasudil target RHOA in situ,
immunofluorescence microscopy was performed on paraffin sections of
stomachs (Figure 6A). RHOA was readily detectable in both
fasudil-treated and PBS-control gastric tumor tissue but not in
non-neoplastic stomach regions (corpus) of the same transgenic
animals. The staining intensity of two exemplary down-stream
target proteins of the RHO-pathway, p38 and ERK1/2(p44/p42), by
phosphorylation-specific Abs was decreased in tumor regions of treated
mice (S8). We finally asked whether fasudil also diminishes ROCK2
phosphorylation in vivo. To this end, fresh frozen samples of liver tissue
from fasudil-treated and PBS-control tumor-bearing CEA424-SV40
TAg mice were subjected to total protein lysate extraction followed by
ex vivo immunoprecipitation (“IP”) of P-ROCK2 and detection by
P-ROCK2 Ab (“IB”) (Figure 6B). The quantification of WBs evinced
that fasudil treatment decreased P-ROCK2 protein from amean optical
density (O.D.) value of 20.95 ± 18.59 to 0.72 ± 0.37 (n = 8 mice per
group, P= .0379 Ab FASU vs. Ab PBS, Mann-Whitney U test)
compared with PBS-injected controls. Collectively, these results
emphasized that ROCK1/2-inhibitors are able to physically reach the
target organ of interest, the normal and malignant stomach tissue, and
exert long-term preclinical efficacy to reduce tumor growth and lower
the activity of the RHO-signaling pathway in vivo, thus proposing
ROCK1/2 as a potential novel target for treatment of human GC.
Discussion
In this study, we demonstrate for the first time that pharmacological
inhibition of the RHOA-ROCK1/2 signaling pathway inhibits tumor
growth in a genetically driven mouse model of GC. Three recent
Nature publications [3–5] evinced that mutations in components of
the RHO-signaling pathway (RHOA, ARHGAP) frequently occur in
patients with diffuse GC. Genomic data from the TCGA Network
[3] (as reviewed in [1,2]) proposed that similar to colorectal cancer,
GC disease can be subdivided into at least four different subtypes,
resulting in a novel classification system that is likely to replace the
traditional (“Lauren”) distinction of intestinal, diffuse and mixed
types of GC which was based mainly on histomorphological criteria[42]. The new classification system may thus be of high relevance for
future strategies in diagnosis, prognosis and treatment of patients. It is
expected to open novel options for cancer therapy and response
prediction in personalized medicine, where cases are stratified
according their RHOA mutation characteristics as now routinely
implemented for BRAF/NRAS/KRAS mutations in colorectal cancer
and melanoma patients. These novel four subtypes [3] comprise
diffuse genomically stable GC with RHOA-mutations, anti-viral
immune response (EBV), chromosomal instability (CIN) and
epigenetic/methylator (MSI) phenotypes, very similar to the
subclassification of colorectal cancer, indicating a conserved cascade
of genetic alterations in the upper and lower gastrointestinal tract.
Pharmacological inhibitors of the RHO-signaling pathway have
been under (pre) clinical development for many years [11–13]. The
downstream effector kinases ROCK1/2 of RHOA are attractive
targets for small molecule inhibitors, and fasudil is a first-in-class
ROCK inhibitor that has been approved for the treatment of patients
with cerebrovascular complication in Asia. Because RHOA mutations
have been identified as major oncogenic drivers of the diffuse type of
GC [3–5], we tested the hypothesis that inhibition of the
RHO-signaling pathway shall reduce gastric tumor growth in vivo.
We resorted to a transgenic mouse model of GC [27], where the viral
oncogene SV40 large T-antigen is expressed as a transgene under the
human CEA promoter specifically in the lower stomach (pylorus) of
the mice, and which has been successfully subjected to pharmaco-
logical intervention by us before [32,43,44]. This tumor is
characterized by early onset (within 4 weeks of age), a high
proliferation index and up-regulation of stem cell (Wnt/Notch)
[45] and neuroendocrine differentiation signatures [28] culminating
in a small cell carcinoma of the lower part of the mouse stomach, the
pylorus. At late stages, microinvasion and prolaps of luminal tumor
nests toward the upper duodenum can be observed. Due to the
anatomical localization, the dedifferentiated histomorphology, the
highly proliferative nature and genetic signatures (e.g. for cell adhesion
and migration [28]), we employed this mouse strain as a surrogate
model for human diffuse GC. Our identification of PC(34:1)+K+ ,
which has earlier been described as a marker of human GC [41], as an
equivalent marker of CEA424-SV40 TAg transgenic mouse
carcinoma supports this view and suggests that this phosphatidyl-
choline may be a suitable lipidomic biomarker in future translational
studies. The identity of the lipid tumor marker was established by
MALDI TOF MS/MS and FTICR-MS/MS.
In this model, drug-target engagement was suggested by imaging
methodologies and ex vivo biochemical analyses. MALDI-MSI [32]
confirmed rapid in situ distribution and metabolism [40] of fasudil
and its metabolite hydroxyfasudil in liver and normal stomach tissue
of wild-type (WT) mice and in gastric tumor tissue of transgenic
mice. Unexpectedly, the highest ion intensities for the two
compounds were located in the non-malignant upper part of the
stomach (corpus), whereas lower signal intensities were found in the
tumor regions of the lower stomach (pylorus).
Drug penetration into tumor tissues is a major issue for efficient
treatment of cancers, especially of those tumors with strong
desmoplastic reactions and fibrosis, such as in pancreatic cancer,
where the stroma establishes an impermeable physical barrier to
chemo- and targeted therapy [46,47]. If this principle holds true for
primary or metastatic GC is unknown. In previous studies on
drug-target engagement [32] in CEA424-SV40 TAg mice, we
evinced that the protein of interest is modified within the gastric
Figure 5. Preclinical efficacy of fasudil in gastric tumors of CEA424-SV40 TAg mice. A, 3D PET/CT in situ detection of gastric tumors in mouse
stomachs. Signals from [18F]-FDG uptake in fasudil-treated (4 weeks) and PBS-control CEA424-SV40 TAg mice were analyzed by PET and CT
imagingandoverlay. Representative imagesof twoanimals per group are shown.Signal intensity from [18F]-FDGuptake is presented as agraded
color code with a SUVbw range of 0.5–10. Legend: tu, tumor; bl, bladder. The white arrow points at the gastric tumor between the two kidneys
andbelow theheart.B, 3Dquantificationof the tumor volumesbyPET/CT. Signals from [18F]-FDGuptake valueswere calculated asmean (cm3)±
S.E. (n = 12 mice per group, P= .0089 FASU vs. PBS over all SUV ranges, Mann-Whitney U test). Representative histological images and
quantitative analyses are shown. Legend: tu, tumor; sm, smoothmuscle; gl, normal gland (pylorus).C, 2D quantification of the tumor areas. H&E
stained paraffin sections of fasudil-treated (4weeks) andPBS-control CEA424-SV40 TAgmiceweremeasured. Tumor areas (markedwith dotted
lines)were calculatedasmean (mm2)±S.E. (n=23micepergroup,P=.0021FASU vs.PBS,Mann-WhitneyU test).D, 2Dquantificationof tumor
proliferation. Paraffin sections of fasudil-treated (4 weeks) and PBS-control CEA424-SV40 TAg mice were subjected to immunohistochemistry
(IHC) using Ki-67 Ab. The number of Ki-67 positive cells was calculated as means ± S.E. (n = 4mice per group, P= .0407 FASU vs. PBS, t test).
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Figure 6. Fasudil lowers RHO-pathway signaling in gastric tumors of CEA424-SV40 Tag mice. A, In situ detection of elevated RHOA
protein by immunofluorescencemicroscopy inmurine GC compared with normal gastric tissue (corpus). FFPE sections from stomachs of
fasudil-treated and PBS-control CEA424-SV40 TAg mice were subjected to triple-color staining. Legend: Red, RHOA; Green, Actin
(phalloidin); blue, nuclei (DAPI); magnification ×400. Representative images are shown.B, Fasudil inhibits RHOA-pathway activity in
murine GC. Whole tissue lysates from fasudil-treated and PBS-control CEA424-SV40 TAg mice were subjected to immunoprecipitation
(IP) with P-ROCK2 Ab, followed by WB detection (IB) using the same Ab. HSP90 was not precipitated and served as a control for equal
loading (input). O.D. values from band in gels were normalized to HSP90 and calculated as -fold ± S.E. (n = 8mice per group, P= .0379 Ab
FASU vs. Ab PBS, Mann-Whitney U test).
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cells to bind to the target protein. Accelerated drug metabolism in
metabolically active tumor tissue can also explain the different
intensities compared with normal tissue [48]. In contrast to histone
acetylation as a readout for epigenetic drug action in situ [32,43],
suitable mass targets for detection of ROCK1/2 inhibition are
currently lacking for detection by MALDI-MSI and constitute a
challenge for future developments.
Nonetheless, we confirmed the presence of the drug target proteins
by methods not based on imaging. Expression of RhoA mRNA and
RHOA protein was visible in immunofluorescence microscopy and
upon ex vivo WBs and PCR. The TCGA-powered genetic studies
[3–5] did not clarify whether the observed RHOA gene mutations in
human GC samples result in a gain (GOF) or loss (LOF) of RHOA
protein function. Thus, it remains elusive if the GTPase activity or
the recruitment of downstream effectors of the mutant RHOA
protein is altered in a positive or negative mode. Experimental
evidence is lacking, but the stakes are for a gain of protein function
similar to the oncogenic driver mutations in the KRAS gene, which
lead to RAS proteins locked in a GTP-bound constitutively active
state that drives initiation and progression of pancreatic, lung and
colorectal cancer. Previous in vitro studies proposed that
RHO-signaling is active in human GC cell lines [19,20] and the
malignant phenotypes of those cells can be reversed by ROCK1/
2-inhibition [24–26]. However, the function of RHOA in vivo
remained unknown. We collected a priori evidence that a GOF is
likely for our GC mouse model. Total protein levels of RHOA and its
cognate substrate ROCK1/2 but not RHOA activities were elevated
in gastric tumor tissue compared to adjacent normal stomach tissue of
the transgenic mice. We were unable to detect elevated RHOA
activity in GST-pulldown assays using the substrate rhotekin as bait
in whole tissue lysates of mice stomachs. Nonetheless, we could see an
increase of active phosphorylated ROCK1/2 protein, another
candidate of a diverse set of RHOA downstream substrates [6,11].
Concluding from these data, a GOF of RHOA protein was stated for
our model. If this holds true for human samples and other mouse
models of GC has to be studied in the future.
After having collected evidence that both drug and target are
present in the tumor, the preclinical efficacy of fasudil was monitored
in living animals by PET/CT and post mortem by histopathological
examination. Consistent with the known high metabolic and
proliferative activity of the gastric tumor [27,28,45], [18F]-FDG
uptake was clearly visible in an anatomical area corresponding to the
localization of the pylorus, below the heart and above the two kidney
signals. The 3D tumor volume (SUV (ccm)) was significantly reduced
in therapy vs. control mice. The 4-weeks treatment with a daily dose
of fasudil (10 mg/kg) not only diminished [18F]-FDG uptake in
living mice, but also post mortem histopathological analysis confirmed
reduction of the 2D tumor area and the proliferation marker Ki-67
in situ. We could also prove that phosphorylation of ROCK1/2
proteins were lowered in fasudil-treated mice compared with controls.
In contrast, total amounts of RHOA proteins in the tumor
were unaffected by the drug, because fasudil acts down-stream of
RHOA. Collectively, we demonstrated in the present study that
RHOA-pathway inhibition attenuated gastric cancer growth in vivo.
Remaining important issues are to explore if RHOA mutations are
also frequent in murine GC in the present transgenic model and other
state-of-the-art murine GC models. Secondly, it has to be assessed
whether RHOA mutations in human or rodent tumors result in aGOF or LOF of RHOA protein levels and/or GTPase activity. Our
collaborators have recently shown that RHOA mutations in diffuse
type of GC do not correlate with a poor prognosis in patients [22,23].
Others [49,50] observed that increased staining positivity for small
GTPase signaling pathway components (including RHOA and
ROCK1) in IHC studies predicts metastasis and a poor survival
prognosis of GC patients. The latter reports are in line with our
findings, because we observed increased total RHOA protein in
tumors but not elevated GTPase activity. Nonetheless, this may also
have been caused by experimental limitations, since rhotekin is only
one of many (N20) substrates of RHOA [6]. Thus, future experiments
have to decide if RHOAmutations render the GTPase more active, or
the increase in total protein amounts of RHOA accounts for the
activation of the ROCK1/2 signaling pathway in tumors. In sum, our
data propose inhibition of the RHOA-ROCK1/2-pathway as a novel
therapy also for human GC.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.07.002.
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